Fed. Circ. Reverses Initial Panel To Find Gilenya IP Invalid
The Federal Circuit held Tuesday that Novartis' patent covering its multibillion-dollar multiple sclerosis drug Gilenya isn't valid after all, reversing an earlier panel that found in favor of the Swiss drugmaking giant....To view the full article, register now.
Already a subscriber? Click here to view full article